Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
NCT05514548 · View on ClinicalTrials.gov ↗
Study Summary
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG INV-202
Study Locations (20)
California
- National Institute of Clinical Research, Inc. — Garden Grove
- National Institute of Clinical Research, Inc - Pomona — Pomona
- Central Coast Nephrology — Salinas
- North American Research Institute — San Dimas
- National Institute of Clinical Research, Inc - Upland — Upland
Florida
- Research Physicians Network Alliance — Boca Raton
- ALL Medical Research, LLC — Cooper City
- South Florida Research Institute — Lauderdale Lakes
Texas
- North Texas Endocrine Center — Dallas
- Biopharma Informatic, LLC — Houston
- Linq Research, LLC — Pearland
Georgia
- Endocrine Research Solutions, Inc. — Roswell
Illinois
- Research by Design, LLC — Chicago
Maryland
- Endocrine and metabolic Consultants — Rockville
Missouri
- Clinical Research Consultants, LLC — Kansas City
Nevada
- Palm Research Center, Inc — Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2022-10-19 |
| Est. Completion | 2024-09-03 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05514548
The ClinicalTrials.gov registry entry for NCT05514548 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inversago Pharma, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Diabetic Kidney Disease appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05514548 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Florida, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05514548 about?
NCT05514548 is a clinical study titled "Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease". The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus.
What is the current status of trial NCT05514548?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 265 participants. The study started on 2022-10-19. Estimated completion is 2024-09-03.
What conditions does trial NCT05514548 study?
This clinical trial studies the following conditions: Diabetic Kidney Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05514548?
The interventions under investigation include: Placebo (DRUG), INV-202 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05514548?
This trial is sponsored by Inversago Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05514548 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.